vs
Side-by-side financial comparison of Iterum Therapeutics plc (ITRM) and MICROVISION, INC. (MVIS). Click either name above to swap in a different company.
Iterum Therapeutics plc is the larger business by last-quarter revenue ($390.0K vs $223.0K, roughly 1.7× MICROVISION, INC.). Iterum Therapeutics plc produced more free cash flow last quarter ($-7.5M vs $-59.4M).
Iterum Therapeutics plc is a clinical-stage biopharmaceutical company specializing in developing innovative anti-infective therapies to treat infections caused by multi-drug resistant bacteria. Its lead product candidate targets indications including community-acquired bacterial pneumonia and complicated urinary tract infections, addressing unmet medical needs across global healthcare markets.
MicroVision Inc. is a technology company specializing in advanced LiDAR sensors, miniature display solutions, and perception software. Its core products serve automotive ADAS, augmented reality devices, consumer electronics, and industrial automation markets, delivering high-precision, low-power sensing technologies for next-generation smart applications.
ITRM vs MVIS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $390.0K | $223.0K |
| Net Profit | $-9.0M | — |
| Gross Margin | — | — |
| Operating Margin | -1982.3% | — |
| Net Margin | -2302.3% | — |
| Revenue YoY | — | -86.5% |
| Net Profit YoY | -47.3% | -21.2% |
| EPS (diluted) | $-0.20 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $223.0K | ||
| Q3 25 | $390.0K | $241.0K | ||
| Q2 25 | — | $155.0K | ||
| Q1 25 | — | $589.0K | ||
| Q4 24 | — | $1.6M | ||
| Q3 24 | — | $190.0K | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $956.0K |
| Q4 25 | — | — | ||
| Q3 25 | $-9.0M | $-14.2M | ||
| Q2 25 | — | $-14.2M | ||
| Q1 25 | — | $-28.8M | ||
| Q4 24 | — | $-31.2M | ||
| Q3 24 | — | $-15.5M | ||
| Q2 24 | — | $-23.9M | ||
| Q1 24 | — | $-26.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 6.6% | ||
| Q4 24 | — | -149.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 18.2% | ||
| Q1 24 | — | -33.6% |
| Q4 25 | — | — | ||
| Q3 25 | -1982.3% | -5278.4% | ||
| Q2 25 | — | -9455.5% | ||
| Q1 25 | — | -2383.7% | ||
| Q4 24 | — | -1119.5% | ||
| Q3 24 | — | -8266.3% | ||
| Q2 24 | — | -1296.4% | ||
| Q1 24 | — | -2793.9% |
| Q4 25 | — | — | ||
| Q3 25 | -2302.3% | -5899.2% | ||
| Q2 25 | — | -9180.0% | ||
| Q1 25 | — | -4886.1% | ||
| Q4 24 | — | -1888.2% | ||
| Q3 24 | — | -8166.8% | ||
| Q2 24 | — | -1259.5% | ||
| Q1 24 | — | -2752.4% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.20 | $-0.05 | ||
| Q2 25 | — | $-0.06 | ||
| Q1 25 | — | $-0.12 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.0M | $74.9M |
| Total DebtLower is stronger | $20.0M | $19.2M |
| Stockholders' EquityBook value | $-7.4M | $55.5M |
| Total Assets | $32.5M | $103.1M |
| Debt / EquityLower = less leverage | — | 0.35× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $74.9M | ||
| Q3 25 | $11.0M | $99.5M | ||
| Q2 25 | — | $91.4M | ||
| Q1 25 | — | $69.0M | ||
| Q4 24 | — | $74.7M | ||
| Q3 24 | — | $43.2M | ||
| Q2 24 | — | $56.6M | ||
| Q1 24 | — | $73.1M |
| Q4 25 | — | $19.2M | ||
| Q3 25 | $20.0M | $29.0M | ||
| Q2 25 | — | $32.3M | ||
| Q1 25 | — | $30.1M | ||
| Q4 24 | — | $33.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $55.5M | ||
| Q3 25 | $-7.4M | $90.7M | ||
| Q2 25 | — | $77.1M | ||
| Q1 25 | — | $53.2M | ||
| Q4 24 | — | $48.8M | ||
| Q3 24 | — | $65.9M | ||
| Q2 24 | — | $78.7M | ||
| Q1 24 | — | $93.8M |
| Q4 25 | — | $103.1M | ||
| Q3 25 | $32.5M | $150.8M | ||
| Q2 25 | — | $140.6M | ||
| Q1 25 | — | $116.7M | ||
| Q4 24 | — | $121.2M | ||
| Q3 24 | — | $88.3M | ||
| Q2 24 | — | $103.4M | ||
| Q1 24 | — | $124.2M |
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.42× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | 0.68× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.4M | $-58.7M |
| Free Cash FlowOCF − Capex | $-7.5M | $-59.4M |
| FCF MarginFCF / Revenue | -1912.6% | -26636.3% |
| Capex IntensityCapex / Revenue | 3.1% | 304.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-103.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-58.7M | ||
| Q3 25 | $-7.4M | $-16.5M | ||
| Q2 25 | — | $-12.7M | ||
| Q1 25 | — | $-14.1M | ||
| Q4 24 | — | $-15.1M | ||
| Q3 24 | — | $-14.1M | ||
| Q2 24 | — | $-18.6M | ||
| Q1 24 | — | $-20.8M |
| Q4 25 | — | $-59.4M | ||
| Q3 25 | $-7.5M | $-16.6M | ||
| Q2 25 | — | $-12.9M | ||
| Q1 25 | — | $-14.2M | ||
| Q4 24 | — | $-15.2M | ||
| Q3 24 | — | $-14.1M | ||
| Q2 24 | — | $-18.8M | ||
| Q1 24 | — | $-20.9M |
| Q4 25 | — | -26636.3% | ||
| Q3 25 | -1912.6% | -6894.6% | ||
| Q2 25 | — | -8346.5% | ||
| Q1 25 | — | -2410.4% | ||
| Q4 24 | — | -918.7% | ||
| Q3 24 | — | -7421.1% | ||
| Q2 24 | — | -989.5% | ||
| Q1 24 | — | -2183.4% |
| Q4 25 | — | 304.5% | ||
| Q3 25 | 3.1% | 53.1% | ||
| Q2 25 | — | 134.2% | ||
| Q1 25 | — | 16.8% | ||
| Q4 24 | — | 6.2% | ||
| Q3 24 | — | 4.7% | ||
| Q2 24 | — | 8.7% | ||
| Q1 24 | — | 11.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
